Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell.

Geoffrey Bosson

Journal: British journal of biomedical science 2003;60(2):117-29

PMID: 12866924

Abstract

The cytotoxic drug methotrexate uses the reduced folate carrier for transport into the cell, where it inhibits key enzymes in nucleotide biosynthesis. Resistance to methotrexate can be achieved by altering the genetic code of the reduced folate carrier gene and thus change the structure and function of the protein. Our understanding of RFC structure and function is based on the information gained from studying the uptake of folates and antifolates in living cells and the application of molecular techniques to determine gene expression and genetic mutations. The aim of this essay is to explain the structure and function of the reduced folate carrier, review the molecular biology of the reduced folate carrier gene and the mutations and polymorphisms that can result in methotrexate resistance.

Address: School of Applied and Molecular Sciences, Ellison Building, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK. [email protected]

Link outs

Free resources

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.